To determine the efficacy of escitalopram in treating depression in HIV seropositive women.
To determine the efficacy of escitalopram in treating depression in HIV seropositive women.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
5
Placebo daily for duration of double-blind portion of trial
Escitalopram 10 mg po daily for duration of double-blind portion of trial
Duke University Medical Center
Durham, North Carolina, United States
Reduction in Depressive Symptoms
Depressive symptoms were assessed by questionaire at baseline and finally at the end of the study at 9 weeks.
Time frame: 9 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.